RE:CCR JournalStockhouse Logo
Search Companies, etc
Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation
Oncolytics Biotech Ord Shs T.ONC
Alternate Symbol(s): ONCY
Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
New Post
TSX:ONC - Post by User
Oncolytics Biotech Ord Shs
> G12D/G12V KRAS mutation in PC & CRC patients respond to Pela
<< Previous
Bullboard Posts
User Avatar Image
(4264)
•••
Comment by Noteableon Dec 18, 2023 9:09pm
2 Views Post# 35790975
RE:RE:G12D/G12V KRAS mutation in PC & CRC patients respond to Pela
December 15, 2023 -
Translational Relevance
Pelareorep (PELA) is an oncolytic virus formulation that is currently being investigated for multiple myeloma therapy. Our study shows that combination PELA, bortezomib, and dexamethasone therapy is safe, well-tolerated, and induces an inflammatory response in patients with multiple myeloma characterized by significant T and natural killer cell activation, enhanced chemokine release, bone marrow T-cell infiltration, and increased programmed death-ligand 1 expression in multiple myeloma cells. Multiplexed immune cell profiling of the tumor immune microenvironment (TiME) defined a novel immune-primed multiple myeloma phenotype (CD138+IDO1+HLA-ABCHigh) and revealed increased interactions between multiple myeloma and immune cell subsets in bone marrow from responders compared with nonresponders. Our findings support further investigation of oncolytic virotherapy-driven immune reprogramming as a potential strategy for sensitizing immunologically “cold” tumors to immune checkpoint inhibitor therapies. Additionally, our study demonstrates that TiME immune cell profiling should be explored as a potential clinical tool to distinguish early responders and nonresponders.